Literature DB >> 9603914

Minor modifications of a cholecystokinin-B/gastrin receptor non-peptide antagonist confer a broad spectrum of functional properties.

M Beinborn1, S M Quinn, A S Kopin.   

Abstract

The development of non-peptide agonists for peptide hormone receptors would markedly expand the treatment options for a large number of diseases. However, difficulty in identifying non-peptide molecules which possess intrinsic activity has been a major obstacle in achieving this goal. At present, most of the known non-peptide ligands for peptide hormone receptors appear in standard functional assays to be antagonists. Here, we report that a constitutively active mutant of the human cholecystokinin-B/gastrin receptor, Leu325 --> Glu, offers the potential to detect even trace agonist activity of ligands which, at the wild type receptor isoform, appear to lack efficacy. The enhanced functional sensitivity of the mutant receptor enabled us to detect intrinsic activity of L-365,260, an established non-peptide antagonist for the cholecystokinin-B/gastrin receptor. Extending from this observation, we were able to demonstrate that minor structural modifications could convert L-365, 260 into either: (i) an agonist or (ii) an inverse agonist (attenuates ligand-independent signaling). The ability to confer functional activity to small non-peptide ligands suggests that the properties of endogenous peptide hormones can be mimicked, and even extended, by considerably less complex molecules.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603914     DOI: 10.1074/jbc.273.23.14146

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Pharmacological comparison of the alternatively spliced short and long CCK2 receptors.

Authors:  M F Morton; E A Harper; I A Tavares; N P Shankley
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

2.  Identification of a series of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation.

Authors:  Alan S Kopin; Edward W McBride; Ci Chen; Roger M Freidinger; Duan Chen; Chun-Mei Zhao; Martin Beinborn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

3.  Actions of the small molecule ligands SW106 and AH-3960 on the type-1 parathyroid hormone receptor.

Authors:  Percy H Carter; Thomas Dean; Brijesh Bhayana; Ashok Khatri; Raj Rajur; Thomas J Gardella
Journal:  Mol Endocrinol       Date:  2015-01-13

4.  Presence of CCK-A, B receptors and effect of gastrin and cholecystokinin on growth of pancreatobiliary cancer cell lines.

Authors:  Jin-Young Jang; Sun-Whe Kim; Ja-Lok Ku; Yong-Hyun Park; Jae-Gahb Park
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

Review 5.  Structural basis of cholecystokinin receptor binding and regulation.

Authors:  Laurence J Miller; Fan Gao
Journal:  Pharmacol Ther       Date:  2008-05-11       Impact factor: 12.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.